**OLERUP SSP** 

HLA-C\*16 **Product Insert** Page 1 of 20 **101.627-12 – including** *Taq* **polymerase**, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for "Instructions for Use" (IFU)

**101.627-12u – without** *Taq* **polymerase**, IFU-02

Lot No.: 1K6 Lot-specific information

Olerup SSP® HLA-C\*16

**Product number:** 101.627-12 - including *Taq* polymerase

101.627-12u – without *Taq* polymerase

Lot number: 1K6

Expiry date: 2023-09-01

Number of tests: 12 Number of wells per test: 23+1

Storage - pre-aliquoted primers: dark at -20°C

> - PCR Master Mix: -20°C - Adhesive PCR seals RT - Product Insert RT

## This Product Description is only valid for Lot No. 1K6.

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

## CHANGES COMPARED TO THE PREVIOUS OLERUP SSP® HLA-C\*16 Lot (0H4)

- The product documentation has been updated for new alleles of IMGT 3.36.0
- The kit resolution focuses on common and well documented (CWD) alleles1.

The HLA-C\*16 primer set, specificity and interpretation tables have been updated for the HLA-C alleles described since the previous Olerup SSP® HLA-C\*16 lot was made (Lot No. 0H4).

<sup>1</sup>S. J. Mack, P. Cano, J. A. Hollenbach et al. Common and well-documented HLA alleles: 2012 update to the CWD catalogue. Tissue Antigens, 2013, 81, 194-203

The primers of the wells detailed below have been exchanged, added or modified compared to the previous lot.

Well	5'-primer	3'-primer	rationale
2	Exchanged	Added	5'-primer exchanged for improved yield.
			3'-primer added for the C*16:02:15 allele.

**Product Insert** 

Page 2 of 20

**101.627-12 – including** *Taq* **polymerase**, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for **101.627-12u – without** *Taq* **polymerase**, IFU-02

"Instructions for Use" (IFU)

Lot No.: 1K6 **Lot-specific information** 

Well 24 contains Negative Control primer pairs, that will amplify a majority of the Olerup SSP® HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs. The PCR products generated by the positive control primer pair are 200 and 430 base pairs.

Length of PCR	105	200	105	80	75	80	85
product							
5'-primer <sup>1</sup>	164	340	440	45	45	43	36
	5'-CAC3'	<sup>5'</sup> -Agg <sup>3'</sup>	<sup>5'</sup> -TTA3'	<sup>5</sup> '-Tgg <sup>3</sup> '	<sup>5</sup> '-Tgg <sup>3</sup> '	<sup>5</sup> '-Tgg <sup>3</sup> '	<sup>5'</sup> -TAC <sup>3'</sup>
							36
							<sup>5'</sup> -TAT <sup>3'</sup>
3'-primer <sup>2</sup>	231	2 <sup>nd</sup> I	507	59	58	57	47
•	<sup>5</sup> '-TgC <sup>3</sup> '	<sup>5'</sup> -AAA <sup>3'</sup>	<sup>5'</sup> -TTg <sup>3'</sup>	<sup>5'</sup> -CTC <sup>3'</sup>	<sup>5'</sup> -ggC <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ACA3'
							48
							<sup>5'</sup> -gCA <sup>3'</sup>
							48
							<sup>5'</sup> -gCC <sup>3'</sup>
							52
							<sup>5</sup> '-TgT <sup>3</sup> '
A*	+	+	+				
B*	+	+	+				
C*	+	+	+				
DRB1				+	+		
DRB3				+	+		
DRB5				+			
DQB1					+		
DPB1						+	
DQA1							+

<sup>1</sup>The nucleotide position for HLA class I genes and the codon for HLA class Il genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codonnumbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>2</sup>The nucleotide position for HLA class I genes and the codon for HLA class Il genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon or the 2<sup>nd</sup> intron, matching the specificitydetermining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

HLA-C\*16 **Product Insert** Page 3 of 20

**101.627-12 – including** *Taq* **polymerase**, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for **101.627-12u – without** *Taq* **polymerase**, IFU-02

"Instructions for Use" (IFU)

Lot No.: 1K6 Lot-specific information

## PRODUCT DESCRIPTION

## HLA-C\*16 SSP typing

#### CONTENT

The primer set contains 5'- and 3'-primers for identifying the C\*16:01 to C\*16:152 alleles.

#### PLATE LAYOUT

Each HLA-C\*16 test consists of 24 PCR reactions in a 24 well cut PCR plate.

1	2	3	4	5	6	7	8
9	10	11	12	13	14	15	16
17	18	19	20	21	22	23	NC

The 24 well PCR plate is marked with 'HLA-C\*16' in silver/gray ink.

Well No. 1 is marked with the Lot No. '1K6'.

Wells 1 to 23 – HLA-C\*16 high resolution primers.

Well 24 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded. The PCR plates are heat-sealed with a PCR-compatible foil.

Please note: When removing each 24 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

#### INTERPRETATION

Due to the sharing of sequence motifs between HLA-C alleles, non-HLA-C\*16 alleles will be amplified by some primer mixes. For further details see Specificity Table.

#### **UNIQUELY IDENTIFIED ALLELES**

All the HLA-C\*16 alleles, i.e. C\*16:01 to C\*16:152, recognized by the HLA Nomenclature Committee in April 2019<sup>1,2</sup> will be amplified by the primers in the HLA-C\*16 SSP kit<sup>3</sup>.

The HLA-C\*16 kit enables separation of the confirmed HLA-C\*16 alleles as listed in the IMGT/HLA database 3.25.0. An HLA allele is listed as confirmed by IMGT/HLA if it has been sequenced by more than a single laboratory or from multiple sources. Current allele confirmation status for HLA-C\*16 alleles is listed below.

**■LERUP SSP** 

HLA-C\*16 Product Insert Page 4 of 20 101.627-12 – including *Taq* polymerase, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for 101.627-12u – without *Taq* polymerase, IFU-02 "Instructions for Use" (IFU)

Lot No.: 1K6 Lot-specific information

The HLA-C\*16 kit also enables identification of many null and alternatively expressed alleles.

The following HLA-C\*16 alleles can be distinguished by the different sizes of the HLA-specific PCR product:

Alleles	Primer mix	Alleles	Primer mix
C*16:15:01-16:15:02, 16:20	11	C*16:27, 16:32	20
C*16:16Q, 16:17	12	C*16:28, 16:31, 16:50	19
C*16:24, 16:58	22	C*16:30N, 16:56	23

<sup>1</sup>HLA-C alleles listed on the IMGT/HLA web page 2019-April-17, 3.36.0, <a href="www.ebi.ac.uk/imgt/hla">www.ebi.ac.uk/imgt/hla</a>. <sup>2</sup>Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <a href="http://hla.alleles.org/alleles/deleted.html">http://hla.alleles.org/alleles/deleted.html</a>.

<sup>3</sup>The HLA-C\*16 primer set cannot separate the 16:04:01:01-16:04:01:02, 16:04:04-16:04:05, 16:33, 16:66, 16:78, 16:82, 16:109, 16:124, 16:149-16:150 and the C\*12:176 alleles. These alleles can be distinguished by the HLA-C low resolution kit and/or the HLA-C\*12 high resolution kit.

**●LERUP SSP** 

HLA-C\*16

#### **Product Insert**

Page 5 of 20

**101.627-12 – including** *Taq* **polymerase**, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for **101.627-12u – without** *Taq* polymerase, IFU-02

"Instructions for Use" (IFU)

Lot No.: 1K6 Lot-specific information

#### **ALLELE CONFIRMATION STATUS**

Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>
C*16:01:01:01	Confirmed	C*16:07:02	Confirmed	C*16:45	Confirmed	C*16:85	Unconfirmed
C*16:01:01:02	Unconfirmed	C*16:08	Confirmed	C*16:46	Confirmed	C*16:86	Unconfirmed
C*16:01:02	Unconfirmed	C*16:09	Unconfirmed	C*16:47	Unconfirmed	C*16:87	Unconfirmed
C*16:01:03	Confirmed	C*16:10	Unconfirmed	C*16:48	Unconfirmed	C*16:88	Unconfirmed
C*16:01:04	Confirmed	C*16:11	Unconfirmed	C*16:49	Confirmed	C*16:89N	Unconfirmed
C*16:01:05	Confirmed	C*16:12	Unconfirmed	C*16:50	Confirmed	C*16:90	Unconfirmed
C*16:01:06	Unconfirmed	C*16:13	Confirmed	C*16:51	Unconfirmed	C*16:91	Unconfirmed
C*16:01:07	Unconfirmed	C*16:14	Confirmed	C*16:52	Confirmed	C*16:92	Unconfirmed
C*16:01:08	Unconfirmed	C*16:15:01	Confirmed	C*16:53	Unconfirmed	C*16:93	Unconfirmed
C*16:01:09	Confirmed	C*16:15:02	Unconfirmed	C*16:54	Unconfirmed	C*16:94	Unconfirmed
C*16:01:10	Unconfirmed	C*16:16Q	Confirmed	C*16:55	Unconfirmed	C*16:95	Unconfirmed
C*16:01:11	Unconfirmed	C*16:17	Unconfirmed	C*16:56	Unconfirmed	C*16:96	Unconfirmed
C*16:01:12	Unconfirmed	C*16:18	Confirmed	C*16:57	Unconfirmed	C*16:97	Unconfirmed
C*16:01:13	Unconfirmed	C*16:19	Confirmed	C*16:58	Unconfirmed	C*16:98	Unconfirmed
C*16:01:14	Unconfirmed	C*16:20	Unconfirmed	C*16:59	Unconfirmed		
C*16:01:15	Confirmed	C*16:21	Unconfirmed	C*16:60	Unconfirmed		
C*16:01:16	Unconfirmed	C*16:22	Confirmed	C*16:61	Unconfirmed		
C*16:01:17	Unconfirmed	C*16:23	Unconfirmed	C*16:62	Unconfirmed		
C*16:01:18	Confirmed	C*16:24	Confirmed	C*16:63	Unconfirmed		
C*16:01:19	Unconfirmed	C*16:25	Confirmed	C*16:64	Unconfirmed		
C*16:01:20	Confirmed	C*16:26	Confirmed	C*16:65	Unconfirmed		
C*16:01:21	Unconfirmed	C*16:27	Confirmed	C*16:66	Unconfirmed		
C*16:01:22	Unconfirmed	C*16:28	Unconfirmed	C*16:67	Confirmed		
C*16:02:01	Confirmed	C*16:29	Unconfirmed	C*16:68	Unconfirmed		
C*16:02:02	Confirmed	C*16:30N	Confirmed	C*16:69	Unconfirmed		
C*16:02:03	Confirmed	C*16:31	Unconfirmed	C*16:70	Unconfirmed		
C*16:02:04	Unconfirmed	C*16:32	Unconfirmed	C*16:71	Unconfirmed		
C*16:02:05	Unconfirmed	C*16:33	Unconfirmed	C*16:72	Unconfirmed		
C*16:02:06	Unconfirmed	C*16:34	Unconfirmed	C*16:73	Unconfirmed		
C*16:02:07	Unconfirmed	C*16:35	Confirmed	C*16:74	Unconfirmed		
C*16:02:08	Unconfirmed	C*16:36	Unconfirmed	C*16:75	Unconfirmed		
C*16:02:09	Unconfirmed	C*16:37	Unconfirmed	C*16:76	Unconfirmed		
C*16:02:10	Unconfirmed	C*16:38	Confirmed	C*16:77N	Confirmed		
C*16:02:11	Unconfirmed	C*16:39:01	Confirmed	C*16:78	Unconfirmed		
C*16:02:12	Unconfirmed	C*16:39:02	Unconfirmed	C*16:79	Unconfirmed		
C*16:02:13	Unconfirmed	C*16:40	Confirmed	C*16:80	Unconfirmed		
C*16:04:01	Confirmed	C*16:41	Unconfirmed	C*16:81	Unconfirmed		
C*16:04:03	Confirmed	C*16:42	Confirmed	C*16:82	Unconfirmed		
C*16:06	Unconfirmed	C*16:43	Unconfirmed	C*16:83	Unconfirmed		
C*16:07:01	Unconfirmed	C*16:44	Unconfirmed	C*16:84	Unconfirmed		

<sup>&</sup>lt;sup>1</sup>Allele status "confirmed" or "unconfirmed" as listed on the IMGT/HLA web page 2016-July-14, release 3.25.0, www.ebi.ac.uk/imgt/hla.

#### **RESOLUTION IN HOMO- AND HETEROZYGOTES**

Results file with resolution in HLA-C\*16 homo- and heterozygotes is available upon request.

"Instructions for Use" (IFU)

Lot No.: 1K6

## Lot-specific information **SPECIFICITY TABLE**

# **HLA-C\*16 SSP subtyping**

## Specificities and sizes of the PCR products of the 23+1 primer mixes used for HLA-C\*16 SSP subtyping

Primer Mix	Size of spec. PCR product <sup>1</sup>	Size of control band <sup>2</sup>	Amplified HLA- C*16 alleles <sup>3</sup>	Other amplified HLA Class I alleles
1	210 bp	800 bp	*16:01:01:01- 16:02:17, 16:04:01:01- 16:04:01:02, 16:04:03- 16:04:05, 16:08- 16:21, 16:23- 16:34, 16:36- 16:39:02, 16:41- 16:42, 16:44- 16:47, 16:49- 16:52, 16:54- 16:67, 16:69- 16:87, 16:89N- 16:109, 16:111- 16:112, 16:114- 16:116, 16:118- 16:152	*06:31, 12:176
2	445 bp	1070 bp	*16:02:01- 16:02:17, 16:09, 16:12, 16:19, 16:25, 16:46- 16:48, 16:57, 16:60, 16:63, 16:69-16:70, 16:74, 16:77N, 16:84, 16:88- 16:91, 16:99, 16:101-16:104, 16:107-16:108, 16:115, 16:120, 16:123N, 16:132N-16:133, 16:136, 16:140, 16:143-16:145	*01:14, 01:59, 01:118, 03:07:01:01-03:07:02, 03:15, 03:45, 03:130, 03:140, 03:163, 03:243, 03:268, 03:297, 03:461, 04:01:01-01-04:01:01:29, 04:01:01:31-04:01:28, 04:01:30-04:01:76, 04:01:78-04:01:113, 04:03:01:01-04:10, 04:12-04:20, 04:23-04:28, 04:30-04:35, 04:37-04:54:02, 04:56-04:171, 04:173N-04:213, 04:215N-04:225N, 04:227-04:248, 04:250-04:298, 04:300N-04:375, 05:01:01:01-05:01:45, 05:03-05:128N, 05:130-05:215, 06:02:01:01-06:02:01:17, 06:02:03-06:02:11, 06:02:13-06:02:64, 06:02:66-06:10, 06:12-06:16N, 06:18-06:51, 06:53:01-06:121, 06:123, 06:125-06:146, 06:148-06:216, 06:218-06:235, 06:237-06:243, 06:245-06:247, 06:249-06:251, 06:253-06:263N, 08:10, 12:04:01-12:05, 12:09, 12:21, 12:33, 12:41, 12:54, 12:60, 12:146, 12:188, 14:04, 14:12, 14:49, 14:64, 14:77, 14:108, 17:02, 17:06°-17:16:01°, 17:18°-17:20°, 17:23°-17:29°, 17:31°-17:36°, 17:45°
<b>3</b> <sup>5</sup>	220 bp	800 bp	*16:04:01:01- 16:04:01:02, 16:04:03- 16:04:05, 16:29, 16:33, 16:42, 16:55, 16:61,	*01:04, 01:09, 02:05:01-02:05:03, 02:17, 04:360, 06:02:01:01-06:02:01:17, 06:02:03-06:02:15, 06:02:17-06:02:42, 06:02:44-06:03:02, 06:07-06:13, 06:15-06:34:02, 06:36-06:39, 06:41-06:71, 06:73-06:78, 06:80, 06:82-06:100, 06:102:01-06:117, 06:119-06:122,

HLA-C\*16 Product Insert Page 7 of 20

**101.627-12 – including** *Taq* **polymerase**, IFU-01 **101.627-12u – without** *Taq* **polymerase**, IFU-02

Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for "Instructions for Use" (IFU)

Lot No.: <b>1K6</b>		Lot-specific info	ormation
		16:66, 16:78, 16:82, 16:91, 16:109, 16:124, 16:149-16:150	06:124-06:126, 06:128N-06:135, 06:137-06:142, 06:145-06:152N, 06:154-06:196, 06:198-06:202, 06:205-06:263N, 12:03:01:01-12:03:46, 12:03:48-12:07, 12:11-12:13:01:02, 12:15, 12:23, 12:25-12:26, 12:28-12:29, 12:31-12:35, 12:37-12:39N, 12:42Q-12:43, 12:45-12:48, 12:50-12:55, 12:57:01-12:63, 12:65-12:66, 12:70-12:71, 12:75-12:79, 12:81-12:82, 12:87-12:95, 12:97-12:102, 12:107-12:111, 12:113, 12:115-12:116, 12:119-12:122, 12:125, 12:129, 12:131, 12:133, 12:135, 12:138-12:141, 12:143-12:144, 12:147, 12:149-12:150, 12:152, 12:154, 12:156-12:160, 12:163, 12:165, 12:167, 12:170-12:174, 12:176, 12:178, 12:180, 12:182, 12:184-12:187, 12:189-12:192, 12:194-12:195:03, 12:209-12:211, 12:213, 12:215-12:216, 12:218, 12:220, 12:223, 12:225, 12:227, 12:229-12:230, 12:232N, 12:235, 12:237-12:238, 12:242, 12:244-12:246, 12:248-12:249, 12:253-12:254, 12:256-12:257, 12:259-12:260, 12:278, 12:282, 14:16, <b>B*15:510</b>
4 140 bp	800 bp	*16:01:01:01- 16:01:03- 16:01:15, 16:01:17- 16:01:25, 16:01:27- 16:01:32, 16:04:01:01- 16:04:01:02, 16:04:03- 16:04:05, 16:06- 16:08, 16:10- 16:11, 16:13- 16:18, 16:20- 16:24, 16:26- 16:36, 16:37w, 16:38-16:45, 16:49-16:56, 16:58-16:59, 16:61-16:62, 16:64-16:68, 16:71w, 16:72- 16:73, 16:75- 16:76, 16:78- 16:83, 16:86- 16:87, 16:92- 16:93, 16:95- 16:98, 16:100, 16:105, 16:109- 16:114, 16:116- 16:119, 16:122,	*01:02:34, 01:21, 02:12*, 02:27:01-02:27:02, 02:87, 02:115, 02:126*, 02:131, 03:04:25, 04:11, 04:29, 04:36, 04:55, 04:172, 04:214*, 07:01:74, 07:02:09, 07:583, 07:723, 08:01:01:01-08:02:10, 08:02:12-08:09, 08:11-08:63, 08:65-08:94, 08:95*, 08:96-08:188, 12:02:01-12:02:10, 12:02:12-12:02:22, 12:02:23*, 12:02:24-12:02:27, 12:02:28*, 12:03:01:01-12:03:03, 12:03:05-12:03:08, 12:03:33, 12:03:35-12:03:24*, 12:03:25-12:08, 12:10:01-12:16:01, 12:17-12:20, 12:22-12:26, 12:28-12:32, 12:34-12:40, 12:42Q-12:53, 12:55-12:59, 12:61-12:71, 12:72*, 12:73-12:122, 12:124-12:134, 12:135*, 12:155Q-12:187, 12:189-12:194, 12:195:02, 12:196-12:282, 14:02:03, 14:03:01, 14:08, 14:10, 14:22, 14:35N, 14:38, 14:41, 14:53-14:54, 14:61, 14:70, 14:79, 14:86, 14:90, 15:07, 15:21*, 15:05, B*15:436, B*18:03:02, B*35:08:05, B*67:02

Product Insert

Page 8 of 20

**101.627-12 – including** *Taq* **polymerase**, IFU-01 **101.627-12u – without** *Taq* **polymerase**, IFU-02

Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for "Instructions for Use" (IFU)

	Lot No.: Tr\o		Lot-specific into	Jilladoli
F	160 bp	800 bp	16:124-16:125, 16:127-16:131, 16:134-16:135, 16:137-16:139, 16:141-16:142, 16:146-16:152 *16:01:01-01-	*07:53, 07:216, 14:90, <b>A*24:174</b>
5	ιου υμ	ουυ υμ	16:02:17, 16:06- 16:09, 16:11- 16:28, 16:30N- 16:32, 16:34, 16:36-16:39:02, 16:41, 16:43- 16:44, 16:46- 16:47, 16:49- 16:52, 16:54, 16:56-16:60, 16:62-16:65, 16:69-16:77N, 16:79-16:81, 16:83-16:87, 16:89N-16:90, 16:92-16:102, 16:104-16:108, 16:111-16:123N, 16:125-16:139, 16:141-16:148, 16:151-16:152	07.33, 07.210, 14.30, <b>A 24.174</b>
64	125 bp 160 bp 210 bp	800 bp	*16:11, 16:39:01- 16:39:02 *16:10 *16:06, 16:115	*02:21, 15:191 <b>A*24:106</b> *07:216
74	100 bp 170 bp 210 bp	1070 bp	*16:09 *16:45 *16:07:01	*02:34 *04:14, 04:68, 05:112, <b>A*24:96, A*24:146</b>
8	130 bp 160 bp 190 bp 435 bp	1070 bp	*16:08, 16:38 *16:89N *16:123N *16:53, 16:68, 16:88	*08:96, 15:114 *05:169N
94,6	85 bp 140 bp 205 bp	1070 bp	*16:12 *16:52 *16:35, 16:48	*02:79, 04:69 *06:133 *01:160, 06:118, 07:31:01-07:31:02, 07:177, 07:514, 14:15, 14:87
10	215 bp 350 bp	800 bp	*16:19 *16:13, 16:61	*03:420, 04:101, 05:117, 07:114, 07:557, 08:135 *02:159, 02:161, 05:81, 06:87, 07:24, 07:218, 12:45, 12:166, 14:65
11	170 bp 540 bp	1070 bp	*16:20 *16:15:01- 16:15:02, 16:25, 16:64	*15:75, <b>A*24:73, A*24:157, B*07:66, B*51:55</b> *04:14, 04:68, 07:53, 07:216
124	100 bp 210 bp	1070 bp	*16:17, 16:67 *16:22	*01:27

**Product Insert** Page 9 of 20

101.627-12 – including *Taq* polymerase, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for 101.627-12u – without *Taq* polymerase, IFU-02 "Instructions for Use" (IFU)

L	ot No.: 1 1 10		Lot-specific in	iormation
	245 bp		*16:16Q	
13	130 bp 190 bp 240 bp	1070 bp	*16:14 *16:123N *16:77N	*06:32, 12:40 *02:121N, 06:171:01:01N-06:171:01:02N, 07:164N, 07:451N
14 <sup>6</sup>	210 bp	1070 bp	*16:18, 16:23, 16:104	*14:90
154	85 bp 120 bp 145 bp	1070 bp	*16:04:03 *16:39:01- 16:39:02 *16:21, 16:80	*15:191  *02:14:01-02:14:02, 02:107, 02:164, 04:42:01-04:42:02, 04:220, 05:43, 06:05, 07:01:74, 07:02:09, 08:37, 12:16:01, 12:147, 12:195:02, 12:217, 15:23:01-15:23:02, 15:63, 15:138, 15:158
16	165 bp 375 bp	1070 bp	*16:90 *16:06-16:07:02, 16:117	*02:83, 08:24 *01:05, 01:21, 01:36, 01:55, 01:79:01-01:79:02, 01:120, 02:02:01-02:02:03, 02:02:06-02:02:08, 02:02:10-02:02:30, 02:02:32-02:02:48, 02:02:50-02:04, 02:06:01-02:16:02, 02:18-02:36:02, 02:38:01N-02:40:02, 02:42-02:56, 02:58-02:61, 02:63-02:73, 02:75-02:80, 02:82-02:122, 02:124-02:169N, 03:05, 03:13:01:01-03:13:02, 03:25, 03:27, 03:35:01-03:35:02:02, 03:135, 03:167, 03:178, 03:198, 03:267, 03:292, 03:296:01-03:296:02, 03:335, 03:386, 03:407, 04:01:01-04:01:01:29, 04:01:01:31-04:01:23, 04:01:25-04:01:113, 04:03:01:01-04:20, 04:23-04:36, 04:38-04:39, 04:41-04:79, 04:81-04:99, 04:101-04:109, 04:111-04:116, 04:118-04:177, 04:179-04:223:02, 04:225N-04:229, 04:231, 04:233N-04:241, 04:243-04:369N, 04:371N-04:375, 05:01:01:01-05:01:20, 05:01:22-05:01:45, 05:03-05:06, 05:08-05:09:03, 05:11-05:15, 05:17-05:30, 05:32-05:84, 05:86-05:95, 05:97-05:103:02, 05:105-05:106:02, 05:108-05:147, 05:149-05:151, 05:153N-05:174, 05:176-05:213N, 05:215, 06:101, 06:127:01:01-06:127:02, 06:136, 06:144, 07:01:01-01-07:01:10, 07:01:12-07:01:27, 07:01:29-07:02:97, 07:02:99-07:03, 07:02-07:06:01:02, 07:07-07:09, 07:13-07:30, 07:32N-07:33N, 07:35-07:42, 07:44, 07:46-07:62, 07:64-07:100, 07:102-07:138, 07:140-07:141:02, 07:143-07:194, 07:197-07:271, 07:273-07:294, 07:296-07:301, 07:331, 07:333-07:335, 07:335-07:345, 07:347N-07:353, 07:335-07:327, 07:339-07:345, 07:347N-07:353, 07:335-07:42, 07:443, 07:140-07:141:02, 07:143-07:194, 07:197-07:271, 07:273-07:294, 07:296-07:301, 07:303-07:322, 07:325-07:327, 07:339-07:345, 07:347N-07:353, 07:336-07:402, 07:445, 07:445-07:445, 07:446, 07:445-07:445, 07:445-07:445, 07:445-07:445, 07:445-07:445, 07:445-07:445, 07:445-07:445, 07:446-07:455, 07:447, 07:429-07:443, 07:445-07:446, 07:446-07:455, 07:447, 07:429-07:443, 07:445-07:446, 07:446-07:455, 07:447, 07:429-07:443, 07:445-07:446, 07:446-07:455, 07:447, 07:429-07:443, 07:445-07:446, 07:446-07:455, 07:447, 07:429-07:443, 07:445-07:446, 07:446-07:455, 07:447, 07:429-07:443, 07:464-07:465, 07:468-07:479,

Product Insert Page 10 of 20 use, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for

**HLA-C\*16 Product Ir 101.627-12 – including** *Taq* **polymerase**, IFU-01 **101.627-12u – without** *Taq* **polymerase**, IFU-02

"Instructions for Use" (IFU)

	Lot No.: 1K6		Lot-specific i	nformation
				07:481-07:484N, 07:486, 07:488-07:500, 07:502-07:510, 07:512-07:513Q, 07:515-07:522, 07:524-07:533, 07:536-07:551N, 07:553-07:561, 07:564-07:567, 07:570-07:584, 07:588, 07:590-07:599, 07:601-07:608, 07:610, 07:612-07:621, 07:623-07:625, 07:627-07:650:02, 07:652-07:654, 07:675N-07:692, 07:694-07:697Q, 07:699-07:725, 07:727, 07:729-07:730, 07:732-07:741, 07:743N, 07:745N, 07:748-07:750N, 07:752N-07:757, 07:759-07:775, 07:777-07:779, 08:01:01:01-08:01:10, 08:01:12-08:11, 08:13-08:33:03, 08:35-08:43, 08:45-08:60, 08:62:01-08:63, 08:65-08:81, 08:83-08:125, 08:127N-08:170, 08:172-08:179, 08:181N-08:188, 12:02:01-12:10:02, 12:14:01-12:14:02, 12:16:01-12:18:02, 12:21-12:22, 12:27, 12:30, 12:36, 12:40-12:41, 12:49, 12:56, 12:64, 12:67-12:69, 12:72-12:74, 12:80N, 12:83-12:86, 12:96, 12:103-12:106, 12:112, 12:114, 12:117-12:118, 12:123-12:124, 12:126-12:128, 12:130, 12:132, 12:164, 12:166, 12:168-12:169, 12:177, 12:179, 12:181, 12:128, 12:213, 12:1224, 12:224, 12:224, 12:226, 12:228, 12:231, 12:223, 12:224, 12:226, 12:228, 12:231, 12:233-12:244, 12:2243, 12:224, 12:226, 12:228, 12:231, 12:233-12:244, 12:225, 12:255, 12:261, 12:223, 12:268, 12:275, 12:279-12:281, 14:09, 14:28:02, 15:22, 15:65, 15:72, 15:190, 17:16:01-17:16:02, 18:01:01-18:12
17	180 bp	1070 bp	*16:26, 16:46, 16:55, 16:64 *16:97	*02:49, 02:75, 02:115, 04:01:01:01-04:01:01:29, 04:01:01:31-04:01:09, 04:01:11-04:01:22, 04:01:24-04:01:73, 04:01:74 <sup>w</sup> , 04:01:75-04:01:113, 04:03:01:01-04:07:01, 04:08-04:10, 04:12-04:20, 04:23-04:26, 04:28-04:32, 04:34-04:51, 04:53-04:54:02, 04:56-04:106, 04:108-04:115N, 04:117-04:129, 04:131-04:166:01, 04:167-04:168, 04:170N-04:171, 04:173N-04:230, 04:232-04:282, 04:284-04:375, 05:25, 05:42, 06:05, 06:76:02, 07:01:74, 07:02:09, 07:583, 08:28, 08:137, 08:168, 12:28, 12:132, 12:135, 12:146, 15:25, 15:62, 15:169
184	120 bp 255 bp	1070 bp	*16:38 *16:26, 16:46, 16:55, 16:64	*08:96, 15:114  *01:23, 01:58, 02:49, 02:75, 02:115, 04:01:72, 04:03:01:01-04:03:05, 04:06:01, 04:42:02, 04:80, 04:140, 04:147, 04:160, 04:171, 04:220, 04:256, 04:286, 04:294, 04:299, 04:335, 04:337, 04:351:02, 04:357, 04:363, 05:25, 05:42, 06:02:01:01-06:02:01:17, 06:02:03-06:02:09, 06:02:11-06:25, 06:27-06:29, 06:31-06:52,

Product Insert

Page 11 of 20

**101.627-12 – including** *Taq* **polymerase**, IFU-01 **101.627-12u – without** *Taq* **polymerase**, IFU-02

Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for "Instructions for Use" (IFU)

Lot No.: 1K6 Lot-specific information

			Lot-specific fine	
				06:54-06:124, 06:126-06:131, 06:133-06:168, 06:170-06:197, 06:199-06:203, 06:205-06:209, 06:211N-06:216, 06:218-06:263N, 07:01:01-07:01:22, 07:01:24-07:02:10, 07:02:12-07:02:106, 07:04:01-07:04:04, 07:04:06-07:06:02, 07:08-07:15, 07:17:01-07:19, 07:20:02-07:33N, 07:35, 07:37-07:50, 07:52-07:55N, 07:57-07:58, 07:61N-07:63, 07:65-07:73:01, 07:74-07:78:02, 07:80-07:87, 07:89-07:95, 07:96:02-07:108:02, 07:110-07:126, 07:128-07:172:01, 07:173-07:176, 07:178-07:180, 07:182-07:226, 07:228-07:262, 07:264N-07:294, 07:296-07:314:02, 07:315-07:326, 07:329N-07:354, 07:356-07:366, 07:368:01-07:377, 07:379-07:389, 07:391-07:401, 07:403-07:437N, 07:439-07:441:01, 07:442-07:560, 07:562-07:577, 07:579, 07:581-07:597, 07:599-07:667, 07:669-07:722, 07:724-07:755, 07:757-07:779, 08:28, 08:137, 08:168, 12:28, 12:132, 12:135, 12:146, 15:25, 15:62, 15:169, 17:11, 18:01:01-18:12
194	100 bp 240 bp	800 bp	*16:28, 16:67 *16:29, 16:31, 16:50	*01:108, 06:90 *01:10, 02:05:01-02:05:03, 02:17, 06:08, 06:22, 12:119, 14:25, 17:21, <b>B*07:239, B*14:46,</b> <b>B*14:52, B*40:243</b>
204	95 bp 145 bp 210 bp	1070 bp	*16:27 *16:32 *16:23, 16:104	*05:112 *14:90
21	445 bp 595 bp	1070 bp	*16:40, 16:53, 16:110, 16:113 *16:49	
<b>22</b> <sup>4,7</sup>	85 bp 210 bp	800 bp	*16:58 *16:24	*03:108, 03:150, 04:293, 07:25, 07:404, 15:136
23 <sup>4,6</sup>	95 bp 170 bp	1070 bp	*16:42, 16:56 *16:30N	*04:273, 05:56, 08:69, 12:131
24 <sup>8</sup>	-	-	<b>Negative Control</b>	

<sup>&</sup>lt;sup>1</sup>Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-C\*16 high resolution SSP typings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherit feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

<sup>2</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls



**OLERUP SSP** 

HLA-C\*16 Product Insert Page 12 of 20 101.627-12 – including *Taq* polymerase, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for 101.627-12u – without *Taq* polymerase, IFU-02 "Instructions for Use" (IFU)

Lot No.: 1K6 Lot-specific information

can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>3</sup>For several HLA Class I alleles 1<sup>st</sup> and/or 4<sup>th</sup> exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

<sup>4</sup>HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

<sup>5</sup>Primer mix 3 may give rise to a lower yield of HLA-specific PCR product than the other C\*16 primer mixes.

<sup>6</sup>Primer mixes 9, 14 and 23 may have tendencies of unspecific amplifications.

<sup>7</sup>Primer mix 22 has a tendency to giving rise to primer oligomer formation.

<sup>8</sup>Primer mix 24 contains a negative control, which will amplify a majority of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR products generated by the HGH positive control primer pair are 200 and 430 base pairs.

#### Abbrevations

'w' might be weakly amplified.

'?', nucleotide sequence information not available for the primer matching sequence.

((

**Product Insert** 

Page 13 of 20

101.627-12 – including *Taq* polymerase, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for 101.627-12u – without *Taq* polymerase, IFU-02 "Instructions for Use" (IFU)

Lot No.: 1K6

# **Lot-specific information**

## **PRIMER SPECIFICATION**

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec.	210	445	220	140	160	125	100	130	85	215	170	100
PCR product						160	170	160	140	350	540	210
						210	210	190	205			245
								435				
Length of int.	800	1070	800	800	800	800	1070	1070	1070	800	1070	1070
pos. control <sup>1</sup>												
5'-primer(s) <sup>2</sup>	360	28	361	201	419	113	244	126	256	385	289	361
	5' -CAg 3'	5' -TCA 3'	<sup>5'</sup> -AgT <sup>3'</sup>	5' -CCA 3'	5' -gTC 3'	5' -CCA 3'	5' -CgC 3'	5' -ggA 3'	5' -ACg 3'	5' -ggT 3'	5' -Agg 3'	<sup>5'</sup> -AgT <sup>3'</sup>
	361					124	369	539	361	523	409	
	5' -AgT 3'					5' -gCC 3'	5' -TAC 3'	<sup>5'</sup> -gCg <sup>3'</sup>	<sup>5'</sup> -AgT <sup>3'</sup>	5' -CCg 3'	5' -ggC 3'	
						124	412					
						5' -gCA 3'	<sup>5'</sup> -ATA <sup>3'</sup>					
						368						
						<sup>5'</sup> -gTC <sup>3'</sup>						
						418						
						<sup>5'</sup> -Agg <sup>3'</sup>						
3'-primer(s) <sup>3</sup>	527	302	538	302	539	201	302	205	302	3 <sup>rd</sup> I	539	413
C p		<sup>5'</sup> -qqT <sup>3'</sup>	5' -CCA 3'	5' -qqC 3'		5' -CTT 3'	5' -qqT 3'	5' -CCT 3'	5' -qqT 3'	5' -CTC 3'	5' -TCT 3'	5' -qCC 3'
	527	302				539	539	220	461			427
	5' -CCg 3'	<sup>5'</sup> -ggT <sup>3'</sup>				5' -TCT 3'	5' -TCT 3'	5' -CgA 3'	5' -gCT 3'			<sup>5'</sup> -gTA <sup>3'</sup>
								244	527			530
								5' -CTA 3'	5' -CCg 3'			5' -CCA 3'
								273				563
								5' -TTC 3'				<sup>5'</sup> -CgT <sup>3'</sup>
								3 <sup>rd</sup> I				
								<sup>5'</sup> -gCA <sup>3'</sup>				
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

rimer(s) <sup>2</sup> srimer(s) <sup>3</sup> 5	mer(s) <sup>2</sup> mer(s) <sup>3</sup>	214	368 5'-gTT 3' 539 5'-TCT 3'	97 124 5'-gCA 3' 124 5'-gCC 3' 124 5'-gCC 3' 156 5'-gTA 3' 201	736 5'-gCA 3
rimer(s) <sup>2</sup> srimer(s) <sup>3</sup> 5	mer(s) <sup>2</sup> mer(s) <sup>3</sup>	126 5' -ggA 3' 214 5' -CCA 3' 273 5' -TTC 3' 327	5' -gTg 3' 368 5' -gTT 3' 539 5' -TCT 3'	5° -TCg 3° 124 5° -gCA 3° 124 5° -gCC 3° 156 5° -gTA 3°	5'-AgA 3' 736 5'-gCA 3' 3'd I 5'-CTC 3' 861
rimer(s) <sup>2</sup> srimer(s) <sup>3</sup>	mer(s) <sup>2</sup>	126 5' -ggA 3' 214 5' -CCA 3' 273 5' -TTC 3'	5' -gTg 3' 368 5' -gTT 3' 539 5' -TCT 3'	5° -TCg 3° 124 5° -gCA 3° 124 5° -gCC 3° 156 5° -gTA 3°	5'-AgA 3' 736 5'-gCA 3' 3'd I 5'-CTC 3' 861
rimer(s) <sup>2</sup> srimer(s) <sup>3</sup>	mer(s) <sup>2</sup>	126 5' -ggA 3' 214 5' -CCA 3' 273	5' -gTg 3' 368 5' -gTT 3' 539 5' -TCT 3'	5° -TCg 3° 124 5° -gCA 3° 124 5° -gCC 3° 156 5° -gTA 3°	5'-AgA 3' 736 5'-gCA 3' 3'd I 5'-CTC 3' 861
rimer(s) <sup>2</sup> 5	mer(s) <sup>2</sup>	126 5' -ggA 3' 214 5' -CCA 3'	5' -gTg 3' 368 5' -gTT 3'	5° -TCg 3° 124 5° -gCA 3° 124 5° -gCC 3° 156 5° -gTA 3°	5' -AgA 3 736 5' -gCA 3
rimer(s) <sup>2</sup> 5	mer(s) <sup>2</sup>	126 5' -ggA 3'	5' -gTg 3' 368 5' -gTT 3'	5° -TCg 3° 124 5° -gCA 3° 124 5° -gCC 3° 156 5° -gTA 3°	5' -AgA 3 736 5' -gCA 3
rimer(s) <sup>2</sup>	control <sup>1</sup>	126	<sup>5'</sup> -gTg <sup>3'</sup> 368	5' -TCg 3' 124 5' -gCA 3' 124 5' -gCC 3' 156	<sup>5'</sup> -AgA <sup>3</sup> 736 <sup>5'</sup> -gCA <sup>3</sup>
rimer(s) <sup>2</sup>	control <sup>1</sup>	126	<sup>5'</sup> -gTg <sup>3'</sup> 368	5' -TCg 3' 124 5' -gCA 3' 124 5' -gCC 3' 156	<sup>5'</sup> -AgA <sup>3</sup> 736 <sup>5'</sup> -gCA <sup>3</sup>
rimer(s) <sup>2</sup>	control <sup>1</sup>	126	<sup>5'</sup> -gTg <sup>3'</sup> 368	5' -TCg 3' 124 5' -gCA 3' 124	<sup>5'</sup> -AgA <sup>3</sup> 736 <sup>5'</sup> -gCA <sup>3</sup>
rimer(s) <sup>2</sup>	control <sup>1</sup>	126	<sup>5'</sup> -gTg <sup>3'</sup> 368	5' -TCg 3' 124 5' -gCA 3'	<sup>5'</sup> -AgA <sup>3</sup>
rimer(s) <sup>2</sup>	control <sup>1</sup>	126	<sup>5'</sup> -gTg <sup>3'</sup> 368	<sup>5'</sup> -TCg <sup>3'</sup>	<sup>5'</sup> -AgA <sup>3</sup>
rimer(s) <sup>2</sup>	control <sup>1</sup>	126	<sup>5'</sup> -gTg <sup>3'</sup>	5' -TCg 3'	<sup>5'</sup> -AgA <sup>3</sup>
rimer(s) <sup>2</sup>	control <sup>1</sup>	126			
	control <sup>1</sup>		368	97	361
		1070			
control <sup>1</sup>		1070			
th of int.	h of int.		1070	1070	1070
		240		145	
product	product	190			
h of spec.	of spec.	130		120	375
product	product		1070	145	1070
			ŀ	145	ļ

**OLERUP SSP** 

HLA-C\*16 Product Insert Page 14 of 20 101.627-12 – including *Taq* polymerase, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for 101.627-12u – without *Taq* polymerase, IFU-02 "Instructions for Use" (IFU)

Lot No.: 1K6 Lot-specific information

<sup>1</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>2</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the <a href="www.ebi.ac.uk/imgt/hla">www.ebi.ac.uk/imgt/hla</a> web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>3</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the <a href="www.ebi.ac.uk/imgt/hla">www.ebi.ac.uk/imgt/hla</a> web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.627-12 – including *Taq* polymerase, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for 101.627-12u – without *Taq* polymerase, IFU-02 "Instructions for Use" (IFU)

CELL LINE VALIDATION SHEET																				
HLA-C*16 SSP primer set <sup>2</sup>																				
												W	ell							
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
								_		_										
					401	201908802	201554203	201554204	201554205	201554206	201554207	201898708	201554209	201554210	201554211	201554212	201898713	201554214	201675415	201675416
				Ž	122	88	54	54,	54,	54,	54,	86	54,	54	54	54,	-86	54,	12	122
				Prod. No.:	201675401	319	715	315	715	715	215	78	315	715	315	315	318	315	316	116
				_	2	×	×	×	×	×	×	×	2	×	×	7	×	×	×	7
	IHWC cell line <sup>1</sup>		C*																	
	1 9001 SA 2 9280 LK707		*07:02	*45.05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
2		E4181324	*07:01 *12:02	*15:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
3		GU373	*03:04	*04:01	-	-	-	+	-	-	÷	-	-	-	-	-	-	-	-	+
5		KAS011	*06:02	04.01	H	+	+	÷	-	-	-	-	-	-	-	-	-		-	_
6	9353		*03:04	*07:02	-	-	-		-	-	-	-	-	-	-	-	-		-	+
7	9020		*05:01	07.02	-	+	-	_	-	-	-	-	_	-	-	-	-	-	-	+
8	9007		*04:01		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	+
9	9026		*12:03		-	÷	+	+	-	-	-	-	-	-	-	-	-	-	-	-
10	9107		*01:02		-	-	-	÷	-	-	-	-	-	-	-	-	-	-	-	-
11		PITOUT	*16:01		+	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-
12	9052	DBB	*06:02		-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004	JESTHOM	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071	OLGA	*01:02	*03:04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075	DKB	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16		SWEIG007	*02:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
17		CTM3953540	*03:03	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
18		32367	*01:02	*07:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
19		BM16	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
20		SLE005	*03:04		-	-	-		-	-		-	-	-	-	-	-	_	-	-
21		AMALA	*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22		KOSE	*12:03	*45.00	_	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
23	9124	JBUSH	*01:02	*15:02	-	-	-	÷	-	-	-	-	-	-	-	-	-	-	-	-
24 25	9035		*12:03 *08:02		H	-	+	+	-	-	÷	-	-	-	-	-	-	H	-	+
26		WT49	*07:18		H	-	-	+	-	-	-	-		-	-	-	-		-	+
27		CH1007	*07:10	*15:29	-	-	-		-	-	-	-	-	-	-	-	-		-	-
28		BEL5GB	*05:01	*16:01	+	+	-	+	+	-	-	-	-	-	-	-	-	-	-	+
29	9050		*16:01	10.01	÷	÷	-	+	÷	-	-	-	-	-	-	-	-	-	-	-
30	9021		*17:01		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31		DUCAF	*05:01		-	Ė	-	-	-	-	-	-	-	-	-	-	-	-	-	+
32	9297		*17:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098	MT14B	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104	DHIF	*12:03		-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
35	9302	SSTO	*05:01		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	+
36		KT17	*03:03	*04:01	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	+
37		HHKB	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
38	9099		*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	9315		*02:02	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
40		WHONP199	*01:02	*06:02	-	+	+	÷	-	-	-	-	-	-	-	-	-	Ŀ	-	-
41		H0301	*08:02		-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	+
42		TAB089	*01:02	*00:04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
43		T7526	*01:02	*08:01	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	+
44 45	9057	SHJO	*12:03 *06:02	*17:01	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
46		SCHU	*07:02	17.01	Ε-	+	+	H	÷	÷	÷	-	-	-	÷		-		-	+
47		TUBO	*07:04	*15:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	_
48		TER-ND	*04:01	*16:01	+	+	-	+	+	-	-	-	-	-	-	-	-	-	-	+
40	9303	I LIV-IND	04.01	10.01	ᅼ		_				<u> </u>					ـــــــــــــــــــــــــــــــــــــــ		_	<u> </u>	T

101.627-12 – including *Taq* polymerase, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for 101.627-12u – without *Taq* polymerase, IFU-02 "Instructions for Use" (IFU)

CELL LINE VALIDATION SHEET												
HLA-C*16 SSP primer set <sup>2</sup>												
					17	18	19	20	21	22	23	
					<u> </u>		_					
					201675417	201554218	201554219	201554220	821	201554222	201554223	
				Z .	75	54	54	54	80	54	54	
				Prod. No.:	316	715	75	715	201908821	715	15	
ш					ŏ	Ñ	Ñ	Ñ	Ñ	Ñ	7	
		/C cell line <sup>1</sup>		C*								
1	9001		*07:02	+4= 0=	-	+	-	-	-	-	-	
2		LK707	*07:01	*15:05	-	+	-	-	-	-	-	
3		E4181324	*12:02	*04.04	ļ.	Ŀ	-	-	-	-	-	
4		GU373	*03:04	*04:01	+	÷	-	-	-	-	-	
5	9353	KAS011	*06:02 *03:04	*07:02	ļ-	+	-	-	-	-	-	
6 7	9353		*05:04	07.02	۱ <u>-</u>	+	-	-	-	Ė	-	
8	9020		*04:01		+		-	-	-	-		
9		YAR	*12:03		Ι.	÷	-	-	-	-	-	
10		LKT3	*01:02		1-	Ť	-	-	-	-		
11		PITOUT	*16:01		-	-	-	-	-	-	-	
12	9052		*06:02		-	+	-	-	-	-	-	
13		JESTHOM	*01:02		-	Ė	-	-	-	-	-	
14		OLGA	*01:02	*03:04	1 -	-	-	-	-	-	-	
15	9075		*03:04		-	-	-	-	-	-	-	
16	9037	SWEIG007	*02:02		-	-	-	-	-	-	-	
17	9282	CTM3953540	*03:03	*07:01	-	+	-	-	-	-	-	
18		32367	*01:02	*07:05	-	+	-	-	-	-	-	
19	9038	BM16	*07:01		-	+	-	-	-	-	-	
20	9059	SLE005	*03:04		-	-	-	-	-	-	-	
21	9064	AMALA	*03:03		-	-	-	-	-	-	-	
22	9056	KOSE	*12:03		-	-	-	-	-	-	-	
23	9124	IHL	*01:02	*15:02	-	-	-	-	-	-	-	
24	9035	JBUSH	*12:03		-	-	-	-	-	-	-	
25	9049	IBW9	*08:02		-	-	-	-	-	-	-	
26	9285	WT49	*07:18		-	+	-	-	-	-	-	
27		CH1007	*07:04	*15:29	-	+	-	-	-	-	-	
28		BEL5GB	*05:01	*16:01	-	Ŀ	-	-	-	-	-	
29		MOU	*16:01		-	-	-	-	-	-	-	
30	9021		*17:01		-	-	-	-	-	-	-	
31		DUCAF	*05:01		-	_	-	-	-	-	-	
32		HAG	*17:03		ļ-	-	-	-	-	-	-	
33		MT14B	*03:04		١-	-	-	-	-	-	-	
34	9104		*12:03		-	-	-	-	-	-	-	
35		SSTO	*05:01	*0.4-0.4	H-	_	-	-	-	-	-	
36		KT17	*03:03	*04:01	+	÷	-	-	-	-	-	
37		HHKB	*07:02		μ-	+	-	-	-	-	-	
38 39	9099 9315		*03:03	*07:04	<u> </u>	-	<u> </u>	-	-	-	-	
40		WHONP199	*02:02	*07:01	H	+	-	-	-	-	-	
41		H0301	*01:02 *08:02	*06:02	Η-	+	-	-	-	-	-	
41		TAB089	*01:02		H	Ē	Ē	_	Ē	-	-	
42		T7526	*01:02	*08:01	H	÷	-	-	-	-	-	
44	9076		*12:03	00.01	H	÷	-	-	-	-		
45		SHJO	*06:02	*17:01	<del>  -</del>	+	-	-	-	-	-	
46		SCHU	*07:02	17.01	<del>  -</del>	+	Ė	-	Ė	Ė	-	
47		TUBO	*07:04	*15:02	+-	+	-	-	Ė	-	-	
48		TER-ND	*04:01	*16:01	+	-	-	-	-	-	-	
70	3303	ILITIND	04.01	10.01								

**■LERUP SSP** 

HLA-C\*16 Product Insert Page 17 of 20 101.627-12 – including *Taq* polymerase, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for 101.627-12u – without *Taq* polymerase, IFU-02 "Instructions for Use" (IFU)

Lot No.: 1K6 Lot-specific information

<sup>1</sup>The provided cell line HLA specificities are retrieved from the <a href="http://www.ihwg.org/hla">http://www.ihwg.org/hla</a> web site. The specificity of an individual cell line may thus be subject to change.

<sup>2</sup>The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 6 to 15 and 19 to 23 were available. The specificity of the primers in primer solutions 6 to 9, 11, 12, 14, 15 and 19 to 22 were tested by separately adding one or two additional 5'-primers, respectively one or two additional 3'-primers. In primer solution 10 it was only possible to test the 3'-primer, the 5'-primers were not possible to test. In primer solutions 13 and 23 it was only possible to test the 5'-primer, the 3'-primers were not possible to test. In primer solutions 1, 6, 7, 15 to 17, 20 and 21 one to four of the 5'-primers were not possible to test, and in primer solutions 2, 8, 9, 12, 18, 19 and 22 one to three of the 3'-primers were not possible to test. Additional primers in primer solutions 16 and 17 were tested by separately adding one additional 5'-primer.

**■LERUP SSP**°

HLA-C\*16 Product Insert Page 18 of 20 101.627-12 – including *Taq* polymerase, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for 101.627-12u – without *Taq* polymerase, IFU-02 "Instructions for Use" (IFU)



**■LERUP SSP**°

HLA-C\*16 Product Insert Page 19 of 20 101.627-12 – including *Taq* polymerase, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for 101.627-12u – without *Taq* polymerase, IFU-02 "Instructions for Use" (IFU)

**■LERUP SSP** 

HLA-C\*16 Product Insert Page 20 of 20 101.627-12 – including *Taq* polymerase, IFU-01 Visit <a href="https://labproducts.caredx.com">https://labproducts.caredx.com</a> for 101.627-12u – without *Taq* polymerase, IFU-02 "Instructions for Use" (IFU)

Lot No.: 1K6 Lot-specific information

Addresses:

Manufacturer:

Caredx AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-508 939 00 Fax: +46-8-717 88 18

E-mail: orders-se@caredx.com

Web page: https://labproducts.caredx.com/

Distributed by:

CareDx GmbH, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

**Tel:** +43-1-710 15 00 **Fax:** +43-1-710 15 00 10 **E-mail:** orders-at@caredx.com

Web page: https://labproducts.caredx.com/

CareDx Lab Solutions Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

**Tel:** 1-877-653-78171 **Fax:** 610-344-7989

E-mail: orders-us@caredx.com

Web page: https://labproducts.caredx.com/

For information on CareDx distributors worldwide, contact CareDx GmbH.